Medtronic has completed its $650 million acquisition of SPR Therapeutics and formally launched the ViaVerte system at ASPN 2026, expanding its pain therapy portfolio. The deal adds a non-opioid pain management platform to Medtronic's existing medical device offerings, strengthening its position in interventional pain therapies as clinicians seek alternatives to opioids. The move gives Medtronic a larger footprint in chronic pain treatment and adds a distinct product line alongside its robotics and AI platforms. Medtronic trades at $84.22, roughly 14% below the analyst target of $97.84, and the stock is up 4.0% over the past 30 days.
Medtronic PLCCompletes $650M acquisition and launches new product, expanding pain therapy portfolio.
Acquired by Medtronic for $650M, providing exit for investors.